| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1Section of Neurobiology, Physiology & Behavior, University of California, Davis, California; and 2Regeneron Pharmaceuticals, Tarrytown, New York
Submitted 7 August 2006 ; accepted in final form 15 October 2006
Clenbuterol and other 
2-adrenergic agonists are effective at inducing muscle growth and attenuating muscle atrophy through unknown mechanisms. This study tested the hypothesis that clenbuterol-induced growth and muscle sparing is mediated through the activation of Akt and mammalian target of rapamycin (mTOR) signaling pathways. Clenbuterol was administered to normal weight-bearing adult rats to examine the growth-inducing effects and to adult rats undergoing muscle atrophy as the result of hindlimb suspension or denervation to examine the muscle-sparing effects. The pharmacological inhibitor rapamycin was administered in combination with clenbuterol in vivo to determine whether activation of mTOR was involved in mediating the effects of clenbuterol. Clenbuterol administration increased the phosphorylation status of PKB/Akt, S6 kinase 1/p70s6k, and eukaryotic initiation factor 4E binding protein 1/PHAS-1. Clenbuterol treatment induced growth by 27–41% in normal rats and attenuated muscle loss during hindlimb suspension by 10–20%. Rapamycin treatment resulted in a 37–97% suppression of clenbuterol-induced growth and a 100% reduction of the muscle-sparing effect. In contrast, rapamycin was unable to block the muscle-sparing effects of clenbuterol after denervation. Clenbuterol was also shown to suppress the expression of the MuRF1 and MAFbx transcripts in muscles from normal, denervated, and hindlimb-suspended rats. These results demonstrate that the effects of clenbuterol are mediated, in part, through the activation of Akt and mTOR signaling pathways.
2-adrenergic agonists; mTOR; Akt/PKB; MuRF1; MaFBx
This article has been cited by other articles:
|
|
 |
|
  S. Al-Majid and H. Waters The biological mechanisms of cancer-related skeletal muscle wasting: the role of progressive resistance exercise. Biol Res Nurs, July 1, 2008; 10(1): 7 - 20. [Abstract] [PDF]
|
|
|
|
 |
|
 J. G. Ryall, J. D. Schertzer, T. M. Alabakis, S. M. Gehrig, D. R. Plant, and G. S. Lynch Intramuscular {beta}2-agonist administration enhances early regeneration and functional repair in rat skeletal muscle after myotoxic injury J Appl Physiol, July 1, 2008; 105(1): 165 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sandri Signaling in Muscle Atrophy and Hypertrophy Physiology, June 1, 2008; 23(3): 160 - 170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Lynch and J. G. Ryall Role of {beta}-Adrenoceptor Signaling in Skeletal Muscle: Implications for Muscle Wasting and Disease Physiol Rev, April 1, 2008; 88(2): 729 - 767. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Yang, C. Yang, A. Farberman, T. C. Rideout, C. F. M. de Lange, J. France, and M. Z. Fan The mammalian target of rapamycin-signaling pathway in regulating metabolism and growth J Anim Sci, April 1, 2008; 86(14_suppl): E36 - E50. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. McCarthy and K. A. Esser Counterpoint: Satellite cell addition is not obligatory for skeletal muscle hypertrophy J Appl Physiol, September 1, 2007; 103(3): 1100 - 1102. [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Ryall, J. D. Schertzer, and G. S. Lynch Attenuation of Age-Related Muscle Wasting and Weakness in Rats After Formoterol Treatment: Therapeutic Implications for Sarcopenia J. Gerontol. A Biol. Sci. Med. Sci., August 1, 2007; 62(8): 813 - 823. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
